McGrath J, Saha S, Chant D, Welham J. The epidemiology of schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev
2008; 30: 67–76.
Kirkbride J, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AESOP study. Arch Gen Psychiatry
2006; 63: 250–8.
Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry
2005; 62: 975–83.
Petersen L, Jeppesen P, Thorup A, Øhlenschlæger J, Christensen TØ, Krarup G, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ
2005; 331: 602–5.
Craig TKJ, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ
2004; 329: 1067.
Garety PA, Craig TKJ, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman , et al. Specialised care for early psychosis: symptoms, social functioning, and patient satisfaction. Randomised controlled trial. Br J Psychiatry
2006; 188: 37–45.
Dodgson G, Crebbin K, Pickering C, Mitford E, Brabban A, Paxton R. Early intervention in psychosis service and psychiatric admissions. Psychiatr Bull
2008; 32: 413–6.
Goldberg K, Norman R, Hoch JS, Schmitz N, Windell D, Brown , et al. Impact of a specialized early intervention service for psychotic disorders on patient characteristics, service use, and hospital costs in a defined catchment area. Can J Psychiatry
2006; 51: 895–903.
Mihalopoulos C, McGorry PD, Carter RC. Is phase-specific community orientated treatment of early psychosis an economically viable method for improving outcome?
Acta Psychiatr Scand
1999; 100: 47–55.
Valmaggia L, McCrone P, Knapp M, Woolley JB, Broome MR, Tabraham P, et al. Economic impact of early intervention in people at high risk of psychosis. Psychol Med
2009; 39: 1617–26.
Wing JK, Barbour T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry
1990; 47: 589–93.
Priebe S, Huxley P, Knight S, Evans J. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry
1999; 45: 7–12.
Beecham J, Knapp M. Costing psychiatric interventions. In Measuring Mental Health Needs (ed Thornicroft G): 200–24. Gaskell, 2001.
Netten A, Curtis L. Unit Costs of Health and Social Care. PSSRU, 2004.
Finn W, Hyslop J, Truman C. Mental Health, Multiple Needs and the Police. Revolving Doors Agency, 2000.
Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Int J Technol Assess Health Care
2001; 17: 69–82.
Hoch J, Briggs A, Willan A. Something old, something new, something borrowed, something BLUE: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics
2002; 11: 415–30.
Phillips LJ, Cotton S, Mihalopoulos C, Shih S, Yung AR, Carter R, et al. Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Interv Psychiatry
2009; 3: 28–34.
Calsyn RJ, Allen G, Morse GA, Smith R, Tempelhoff B. Can you trust self-report data provided by homeless mentally ill individuals?
1993; 17: 353–66.
Goldberg RW, Seybolt DC, Lehman A. Reliable self-report of health service use by individuals with serious mental illness. Psychiatr Serv
2002; 53: 879–81.
National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE, 2008.
Williams A. The Role of the EUROQOL Instrument in QALY Calculations.
Centre for Health Economics, University of York, 1995.
Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol
1997; 32: 68–75.
McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ
2009; 12: 27–31.
Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T, Fowler D. Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ–5D. Br J Psychiatry
2009; 195: 170–7.
Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics
2008; 26: 341–58.
Brazier JE, Roberts JF, Deverill MD. The estimation of a preference based measure of health from the SF-36. J Health Econ
2002; 21: 271–92.